TCGA-AO-A12A-01A-21R-A115-07
— · A
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- A
- subtype
- A
- overall_survival_months
- 104
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- WNT_BETA_CATENIN_SIGNALING+0.380
- APICAL_SURFACE+0.360
- UV_RESPONSE_DN+0.330
- TNFA_SIGNALING_VIA_NFKB+0.310
- ESTROGEN_RESPONSE_EARLY+0.300
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.270
- TGF_BETA_SIGNALING+0.270
- APICAL_JUNCTION+0.260
- APOPTOSIS+0.210
- HEDGEHOG_SIGNALING+0.200
Top 10 suppressed
- E2F_TARGETS-0.560
- MYC_TARGETS_V2-0.550
- MYC_TARGETS_V1-0.450
- G2M_CHECKPOINT-0.440
- MTORC1_SIGNALING-0.410
- OXIDATIVE_PHOSPHORYLATION-0.380
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.370
- GLYCOLYSIS-0.310
- PEROXISOME-0.250
- UNFOLDED_PROTEIN_RESPONSE-0.230
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-BH-A0DT-01A-21R-A12D-07 | — | A | 0.901 |
| 2 | TCGA-EW-A1J2-01A-21R-A13Q-07 | — | A | 0.838 |
| 3 | TCGA-E2-A1IO-01A-11R-A144-07 | — | A | 0.835 |
| 4 | TCGA-EW-A1IX-01A-12R-A144-07 | — | A | 0.834 |
| 5 | TCGA-MS-A51U-01A-31R-A266-07 | — | A | 0.833 |
| 6 | TCGA-A2-A0ES-01A-11R-A115-07 | — | A | 0.821 |
| 7 | TCGA-50-8457-01A-11R-2326-07 | — | cohortA1 | 0.817 |
| 8 | SRR6013585 | — | cohortA1 | 0.814 |
| 9 | TCGA-D8-A1JH-01A-11R-A13Q-07 | — | A | 0.813 |
| 10 | TCGA-D8-A27L-01A-11R-A16F-07 | — | A | 0.811 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 24 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| WNT_BETA_CATENIN_SIGNALING | 0.380 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.360 | Temsirolimus | — uncovered |
| UV_RESPONSE_DN | 0.330 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.310 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.300 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.270 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.270 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.260 | Inavolisib | — uncovered |
| APOPTOSIS | 0.210 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.200 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.200 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.170 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.160 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.160 | Inavolisib | — uncovered |
| MYOGENESIS | 0.150 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.140 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.110 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.110 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.100 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.070 | Cobimetinib | — uncovered |